Experiment Protocol Biomedical Engineer in Germany Berlin –Free Word Template Download with AI

This Experiment Protocol outlines the procedures for evaluating a novel biomedical device designed for continuous glucose monitoring (CGM). The study will be conducted in Berlin, Germany, adhering to all relevant national and international regulations, including the German Medical Devices Act (Medizinproduktegesetz, MPG) and the European Union Medical Device Regulation (EU MDR). The primary objective is to assess the accuracy, reliability, and safety of the device in a controlled clinical environment.

The Biomedical Engineer leading this study will ensure that all technical aspects of the device are thoroughly tested, including its integration with existing healthcare systems and its performance under various physiological conditions. The study aims to contribute to the advancement of diabetes management technologies in Germany and beyond.

The primary objectives of this experiment are:

• To evaluate the accuracy of the CGM device compared to standard blood glucose measurements.
• To assess the device's reliability over a 14-day period.
• To identify any potential safety concerns or adverse events associated with the device.
• To gather user feedback on the device's usability and comfort.

This study will be a single-center, prospective, observational trial conducted at a hospital in Berlin, Germany. The study will involve 50 participants diagnosed with Type 1 or Type 2 diabetes. Participants will be recruited through local clinics and diabetes support groups in Berlin.

The study will be divided into three phases:

1. Baseline Assessment: Participants will undergo a comprehensive health evaluation, including blood glucose tests and medical history review.
2. Device Testing: Participants will wear the CGM device for 14 days, during which they will record their blood glucose levels using both the device and a standard glucometer.
3. Follow-Up: Participants will complete a questionnaire assessing their experience with the device, including comfort, ease of use, and any adverse events.

This study will be conducted in accordance with the Declaration of Helsinki and the ethical guidelines of the Berlin Senate Department for Health and Social Affairs. The protocol has been reviewed and approved by the local ethics committee. All participants will provide written informed consent before enrollment. Confidentiality and data protection will be maintained in compliance with the General Data Protection Regulation (GDPR).

Data will be collected using electronic case report forms (eCRFs) and stored in a secure database. The Biomedical Engineer will oversee the data collection process to ensure accuracy and completeness. Statistical analysis will be performed using appropriate software, with a focus on comparing the CGM device's readings to standard blood glucose measurements. The primary endpoint will be the mean absolute relative difference (MARD) between the two methods.

A Data Safety Monitoring Board (DSMB) will be established to review safety data at regular intervals. Any adverse events will be documented and reported to the relevant authorities in Germany. The Biomedical Engineer will work closely with the clinical team to address any technical issues or safety concerns promptly.

This Experiment Protocol provides a comprehensive framework for evaluating a novel biomedical device in Berlin, Germany. By adhering to rigorous scientific and ethical standards, the study aims to contribute valuable insights to the field of biomedical engineering and improve diabetes management for patients in Germany and beyond.